| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01a96e8bbea00eeaa0b50c2a0c000dba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0f9542bb02f9ae5f47cc73451185284 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-4886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate |
2001-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1ffd75022832e093876618859f18a64 |
| publicationDate |
2001-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0180811-A2 |
| titleOfInvention |
Mmp-2 propeptide for use as antiangiogenic or antitumor agent |
| abstract |
Methods and compositions for inhibiting growth of a tumor, inhibiting angiogenesis and inhibiting extracellular matrix destruction in a mammal are disclosed. The method includes administering a therapeutically effective amount of a polypeptide that contains the sequence ProArgCysGlyXaaProAsp, wherein Xaa represents Val or Asn (SEQ ID NO:6). Preferably, the polypeptide is 60 to 100 amino acids in length. In some embodiments, the polypeptide is a human MMP-2 propeptide (SEQ ID NO:1) or an MMP-2 propeptide-like polypeptide, i.e., a polypeptide having at least 80 % sequence identity with SEQ ID NO:1. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8481477-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9395368-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005000342-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2856598-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7629439-B2 |
| priorityDate |
2000-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |